EMEA-002765-PIP01-19
Key facts
| Invented name |
Kisqali
|
| Active substance |
ribociclib succinate
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0218/2020
|
| PIP number |
EMEA-002765-PIP01-19
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of breast cancer
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|